AU2022202770B2 — Compositions and methods for modulating hbv and ttr expression
Assigned to Ionis Pharmaceuticals Inc · Expires 2024-10-03 · 2y expired
What this patent protects
Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine. In certain embodiments, the present disclosure provides conjugated antisense compounds. In certain embodiments, the 5 prese…
USPTO Abstract
Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine. In certain embodiments, the present disclosure provides conjugated antisense compounds. In certain embodiments, the 5 present disclosure provides conjugated antisense compounds comprising an antisense oligonucleotide complementary to a nucleic acid transcript of transthyretin (TTR).
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.